Qualigen Therapeutics Sets 3-for-1 Split, Trading April 29 Under QBAKD
Qualigen Therapeutics will implement a 3-for-1 forward stock split with an ex-date of April 28, 2026, and new shares trading on the OTC Markets starting April 29 under the temporary symbol QBAKD for 20 business days. The company’s market capitalization stands at approximately $64.43 million.
1. Stock Split Announcement
Qualigen Therapeutics has received FINRA clearance for a 3-for-1 forward stock split. The ex-date is April 28, 2026, and trading of the new share structure begins on OTC Markets on April 29 under the temporary symbol QBAKD for 20 business days before reverting to QBAK.
2. Market Capitalization and Trading Profile
The company’s market capitalization is approximately $64.43 million. Over the past 52 weeks, shares have traded between $1.83 and $11.40, with current daily volume around 341 shares, reflecting limited trading activity.
3. Investor Impact
Each existing share will convert into three shares without changing the total investment value initially. This adjustment aims to lower the per-share price to improve affordability and potentially boost trading liquidity among retail investors.